Filing Details

Accession Number:
0001209191-23-019884
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-17 18:21:16
Reporting Period:
2023-03-15
Accepted Time:
2023-03-17 18:21:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1819790 Tarsus Pharmaceuticals Inc. TARS Biological Products, (No Disgnostic Substances) (2836) 814717861
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1841401 Bryan Wahl 15440 Laguna Canyon Road, Suite 160
Irvine CA 92618
General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-03-15 4,790 $0.00 18,513 No 4 M Direct
Common Stock Disposition 2023-03-16 337 $13.43 18,176 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2023-03-15 4,790 $0.00 4,790 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
14,370 No 4 M Direct
Footnotes
  1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
  2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  3. Each RSU represents a contingent right to receive one share of the Company's common stock.
  4. RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.